Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ACT therapy

- PMLiVE

NICE turns down Opdivo for adjuvant melanoma therapy

BMS drug currently only licensed treatment in this setting

- PMLiVE

Novartis wins key adjuvant Taf/Mek approval in Europe

Ex-GSK duo on course for first blockbuster year

- PMLiVE

Novartis considers filings for PI3K drug in breast cancer

Those treated with alpelisib had longer PFS than those on fulvestrant alone

- PMLiVE

Armoured CAR ‘could overwhelm solid tumour resistance’

Eureka Therapeutics and Memorial Sloan Kettering approach shows promise

Keytruda’s secret sauce

Merck’s position in oncology is about much more than a good product

- PMLiVE

Cancer immunotherapy: What’s on the horizon?

Old and new therapies

- PMLiVE

Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member

The latest from pharma, biotech and healthcare

- PMLiVE

Keytruda is first I-O drug cleared for melanoma in China

Company chasing rival BMS in world's biggest market

- PMLiVE

Nanobiotix signs €40m deal with the EIB

loan to fund innovative nanomedicine platform

- PMLiVE

Daily Brief: GSK unveils R&D plan, Keytruda OK’d for lymphoma by NICE

News from pharma, biotech and healthcare

- PMLiVE

China’s BeiGene takes PD-1 antibody into pivotal trials

Firm aims to leapfrog immunotherapy leaders in huge market

- PMLiVE

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

Large portfolios gives companies room for manoeuvre

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links